Treatment and outcomes for locally recurrent rectal cancer in Norway
DOI:
https://doi.org/10.2340/1651-226X.2025.42991Keywords:
Locally recurrent rectal cancer, surgical resection, radiotherapy, reirradiation, overall survival, multimodal treatmentAbstract
Background: The rate of locally recurrent rectal cancer (LRRC) in Norway has decreased due to advancements in surgical techniques and preoperative treatments. Despite this, LRRC continues to present significant morbidity and mortality challenges. This study aims to analyze survival outcomes following different treatment modalities for LRRC in Norway and assess the impact of changes in treatment strategies over time.
Methods: This retrospective study utilized data from the Cancer Registry of Norway, focusing on patients with stage I-III primary rectal cancer treated between 1997 and 2016, who subsequently developed LRRC. Treatment modalities, including surgery, radiotherapy (RT), and re-irradiation (reRT), were analyzed, and the impact of various factors on overall survival (OS) was assessed.
Results: Of the 13,480 patients who underwent surgery for rectal cancer, 827 (6.1%) developed LRRC. For all patients, the median survival from LRRC diagnosis was 18 months, with a 3-year OS of 29%. For patients who underwent surgical resection of LRRC, the 3-year OS was 55% for those who received pre-operative RT, 50% for those who received reRT, and 35% for those without any radiation therapy. For non-operated patients, 3-year OS rates were 22% with RT, 21% with reRT, and 15% for patients without radiation therapy. Patients diagnosed after 2006, patients with early-stage primary cancer, younger age (<75), extended recurrence interval, or well-differentiated tumors had better survival outcomes.
Interpretation: This study describes the outcomes after multimodal treatment approaches for LRRC on a national level over a 20-year period. Patients who underwent surgical resection combined with RT or reRT had the best survival outcomes; however, this group represents a highly selected patient population.
Downloads
References
Heald RJ, Ryall RDH. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet. 1986;327:1479–82.
https://doi.org/10.1016/S0140-6736(86)91510-2 DOI: https://doi.org/10.1016/S0140-6736(86)91510-2
Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30:1926–33.
https://doi.org/10.1200/JCO.2011.40.1836 DOI: https://doi.org/10.1200/JCO.2011.40.1836
Van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12:575–82.
https://doi.org/10.1016/S1470-2045(11)70097-3 DOI: https://doi.org/10.1016/S1470-2045(11)70097-3
Guren MG, Kørner H, Pfeffer F, Myklebust T, Eriksen MT, Edna TH, et al. Nationwide improvement of rectal cancer treatment outcomes in Norway, 1993–2010. Acta Oncol. 2015;54:1714–22.
https://doi.org/10.3109/0284186X.2015.1034876 DOI: https://doi.org/10.3109/0284186X.2015.1034876
Årsrapport for tykk- og endetarmkreft 2022 (Annual report on colorectal cancer). Norway: Cancer Registry of Norway; 2023.
Harris CA, Solomon MJ, Heriot AG, Sagar PM, Tekkis PP, Dixon L, et al. The outcomes and patterns of treatment failure after surgery for locally recurrent rectal cancer. Ann Surg. 2016;264:323–9.
https://doi.org/10.1097/SLA.0000000000001524 DOI: https://doi.org/10.1097/SLA.0000000000001524
Nordkamp S, Voogt ELK, Van Zoggel D, Martling A, Holm T, Jansson Palmer G, et al. Locally recurrent rectal cancer: oncological outcomes with different treatment strategies in two tertiary referral units. Br J Surg. 2022;109:623–31.
https://doi.org/10.1093/bjs/znac083 DOI: https://doi.org/10.1093/bjs/znac083
Camilleri-Brennan J, Steele RJ. The impact of recurrent rectal cancer on quality of life. Eur J Surg Oncol. 2001;27:349–53.
https://doi.org/10.1053/ejso.2001.1115 DOI: https://doi.org/10.1053/ejso.2001.1115
PelvEx Collaborative. Surgical and survival outcomes following pelvic exenteration for locally advanced primary rectal cancer: results from an international collaboration. Ann Surg. 2019;269:315–21.
https://doi.org/10.1097/SLA.0000000000002528 DOI: https://doi.org/10.1097/SLA.0000000000002528
The PelvEx Collaborative. Factors affecting outcomes following pelvic exenteration for locally recurrent rectal cancer. Br J Surg. 2018;105:650–7.
https://doi.org/10.1002/bjs.10734 DOI: https://doi.org/10.1002/bjs.10734
Palmer G, Martling A, Cedermark B, Holm T. A population-based study on the management and outcome in patients with locally recurrent rectal cancer. Ann Surg Oncol. 2007;14:447–54.
https://doi.org/10.1245/s10434-006-9256-9 DOI: https://doi.org/10.1245/s10434-006-9256-9
Westberg K, Palmer G, Hjern F, Johansson H, Holm T, Martling A. Management and prognosis of locally recurrent rectal cancer – a national population-based study. Eur J Surg Oncol. 2018;44:100–7.
https://doi.org/10.1016/j.ejso.2017.11.013 DOI: https://doi.org/10.1016/j.ejso.2017.11.013
Hagemans JAW, Van Rees JM, Alberda WJ, Rothbarth J, Nuyttens J, van Meerten E, et al. Locally recurrent rectal cancer; long-term outcome of curative surgical and non-surgical treatment of 447 consecutive patients in a tertiary referral centre. Eur J Surg Oncol. 2020;46:448–54.
https://doi.org/10.1016/j.ejso.2019.10.037 DOI: https://doi.org/10.1016/j.ejso.2019.10.037
Alberda WJ, Verhoef C, Schipper ME, Nuyttens JJ, Rothbarth J, De Wilt JH, et al. The Importance of a Minimal Tumor-Free Resection Margin in Locally Recurrent Rectal Cancer. Dis Colon Rectum. 2015;58:677–85.
https://doi.org/10.1097/DCR.0000000000000388 DOI: https://doi.org/10.1097/DCR.0000000000000388
Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rödel C, Cervantes A, et al. Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv22–iv40.
https://doi.org/10.1093/annonc/mdx224 DOI: https://doi.org/10.1093/annonc/mdx224
Das P, Delclos ME, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, et al. Hyperfractionated accelerated radiotherapy for rectal cancer in patients with prior pelvic irradiation. Int J Radiat Oncol Biol Phys. 2010;77:60–5.
https://doi.org/10.1016/j.ijrobp.2009.04.056 DOI: https://doi.org/10.1016/j.ijrobp.2009.04.056
Bosman SJ, Holman FA, Nieuwenhuijzen GA, Martijn H, Creemers GJ, Rutten HJ. Feasibility of reirradiation in the treatment of locally recurrent rectal cancer. Br J Surg. 2014;101:1280–9.
https://doi.org/10.1002/bjs.9569 DOI: https://doi.org/10.1002/bjs.9569
Tao R, Tsai CJ, Jensen G, Eng C, Kopetz S, Overman MJ, et al. Hyperfractionated accelerated reirradiation for rectal cancer: an analysis of outcomes and toxicity. Radiother Oncol. 2017;122:146–51.
https://doi.org/10.1016/j.radonc.2016.12.015 DOI: https://doi.org/10.1016/j.radonc.2016.12.015
Lee J, Kim CY, Koom WS, Rim CH. Practical effectiveness of re-irradiation with or without surgery for locoregional recurrence of rectal cancer: a meta-analysis and systematic review. Radiother Oncol. 2019;140:10–9.
https://doi.org/10.1016/j.radonc.2019.05.021 DOI: https://doi.org/10.1016/j.radonc.2019.05.021
Guren MG, Undseth C, Rekstad BL, Braendengen M, Dueland S, Spindler KL, et al. Reirradiation of locally recurrent rectal cancer: a systematic review. Radiother Oncol. 2014;113:151–7.
https://doi.org/10.1016/j.radonc.2014.11.021 DOI: https://doi.org/10.1016/j.radonc.2014.11.021
Van der Meij W, Rombouts AJ, Rutten H, Bremers AJ, de Wilt JH. Treatment of locally recurrent rectal carcinoma in previously (chemo)irradiated patients: a review. Dis Colon Rectum. 2016;59:148–56.
https://doi.org/10.1097/DCR.0000000000000547 DOI: https://doi.org/10.1097/DCR.0000000000000547
Valentini V, Morganti AG, Gambacorta MA, Mohiuddin M, Doglietto GB, Coco C, et al. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: a multicentric phase II study. Int J Radiat Oncol Biol Phys. 2006;64:1129–39.
https://doi.org/10.1016/j.ijrobp.2005.09.017 DOI: https://doi.org/10.1016/j.ijrobp.2005.09.017
Ng MK, Leong T, Heriot AG, Ngan SY. Once-daily reirradiation for rectal cancer in patients who have received previous pelvic radiotherapy. J Med Imaging Radiat Oncol. 2013;57:512–8.
https://doi.org/10.1111/1754-9485.12057 DOI: https://doi.org/10.1111/1754-9485.12057
Helsedirektoratet. Kreft i tykktarm og endetarm – handlingsprogram. 2023, Norwegian Directorate of Health (Helsedirektoratet, Oslo, Norway
Al-Haidari G, Skovlund E, Undseth C, Rekstad BL, Larsen SG, Åsli LM, et al. Re-irradiation for recurrent rectal cancer – a single-center experience. Acta Oncol. 2020;59:534–40.
https://doi.org/10.1080/0284186X.2020.1725111 DOI: https://doi.org/10.1080/0284186X.2020.1725111
Larsen IK, Småstuen M, Johannesen TB, Langmark F, Parkin DM, Bray F, et al. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer. 2009;45:1218–31.
https://doi.org/10.1016/j.ejca.2008.10.037 DOI: https://doi.org/10.1016/j.ejca.2008.10.037
Wittekind C, Compton C, Quirke P, Nagtegaal I, Merkel S, Hermanek P, et al. A uniform residual tumor (R) classification: integration of the R classification and the circumferential margin status. Cancer. 2009;115:3483–8.
https://doi.org/10.1002/cncr.24320 DOI: https://doi.org/10.1002/cncr.24320
Helsedirektoratet. Kreft i tykktarm og endetarm – handlingsprogram. 2022, Norwegian Directorate of Health (Helsedirektoratet, Oslo, Norway.
Roels S, Duthoy W, Haustermans K, Penninckx F, Vandecaveye V, Boterberg T, et al. Definition and delineation of the clinical target volume for rectal cancer. Int J Radiat Oncol Biol Phys. 2006;65:1129–42.
https://doi.org/10.1016/j.ijrobp.2006.02.050 DOI: https://doi.org/10.1016/j.ijrobp.2006.02.050
Radu C, Berglund A, Påhlman L, Glimelius B. Short-course preoperative radiotherapy with delayed surgery in rectal cancer – a retrospective study. Radiother Oncol. 2008;87:343–9.
https://doi.org/10.1016/j.radonc.2007.11.025 DOI: https://doi.org/10.1016/j.radonc.2007.11.025
Åsli LM, Johannesen TB, Myklebust T, Møller B, Eriksen MT, Guren MG. Preoperative chemoradiotherapy for rectal cancer and impact on outcomes – a population-based study. Radiother Oncol. 2017;123:446–53.
https://doi.org/10.1016/j.radonc.2017.04.012 DOI: https://doi.org/10.1016/j.radonc.2017.04.012
Osterman E, Hammarström K, Imam I, Osterlund E, Sjöblom T, Glimelius B. Recurrence risk after radical colorectal cancer surgery-less than before, but how high is it? Cancers (Basel). 2020;12:3308.
https://doi.org/10.3390/cancers12113308 DOI: https://doi.org/10.3390/cancers12113308
Qaderi SM, Galjart B, Verhoef C, Slooter GD, Koopman M, Verhoeven RHA, et al. Disease recurrence after colorectal cancer surgery in the modern era: a population-based study. Int J Colorectal Dis. 2021;36:2399–410.
https://doi.org/10.1007/s00384-021-03914-w DOI: https://doi.org/10.1007/s00384-021-03914-w
Glimelius B, Myklebust T, Lundqvist K, Wibe A, Guren MG. Two countries – two treatment strategies for rectal cancer. Radiother Oncol. 2016;121:357–63.
https://doi.org/10.1016/j.radonc.2016.11.010 DOI: https://doi.org/10.1016/j.radonc.2016.11.010
Fadel MG, Ahmed M, Malietzis G, Pellino G, Rasheed S, Brown G, et al. Oncological outcomes of multimodality treatment for patients undergoing surgery for locally recurrent rectal cancer: a systematic review. Cancer Treat Rev. 2022;109:102419.
https://doi.org/10.1016/j.ctrv.2022.102419 DOI: https://doi.org/10.1016/j.ctrv.2022.102419
Nikolic N, Radosavljevic D, Gavrilovic D, Nikolic V, Stanic N, Spasic J, et al. Prognostic factors for post-recurrence survival in stage II and III colorectal carcinoma patients. Medicina (Kaunas). 2021;57:1108.
https://doi.org/10.3390/medicina57101108 DOI: https://doi.org/10.3390/medicina57101108
Ryuk JP, Choi GS, Park JS, Kim HJ, Park SY, Yoon GS, et al. Predictive factors and the prognosis of recurrence of colorectal cancer within 2 years after curative resection. Ann Surg Treat Res. 2014;86:143–51.
https://doi.org/10.4174/astr.2014.86.3.143 DOI: https://doi.org/10.4174/astr.2014.86.3.143
You YN, Skibber JM, Hu CY, Crane CH, Das P, Kopetz ES, et al. Impact of multimodal therapy in locally recurrent rectal cancer. Br J Surg. 2016;103:753–62.
https://doi.org/10.1002/bjs.10079 DOI: https://doi.org/10.1002/bjs.10079
Susko M, Lee J, Salama J, Thomas S, Uronis H, Hsu D, et al. The use of re-irradiation in locally recurrent, non-metastatic rectal cancer. Ann Surg Oncol. 2016;23:3609–15.
https://doi.org/10.1245/s10434-016-5250-z DOI: https://doi.org/10.1245/s10434-016-5250-z
Johnstone P, Okonta L, Aitken K, Holmes J, Harrison M, Harji D, et al. A multicentre retrospective review of SABR reirradiation in rectal cancer recurrence. Radiother Oncol. 2021;162:1–6.
https://doi.org/10.1016/j.radonc.2021.06.030 DOI: https://doi.org/10.1016/j.radonc.2021.06.030
Collaborative P. Induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer: study protocol of a multicentre, open-label, parallel-arms, randomized controlled study (PelvEx II). BJS Open. 2021;5:zrab029.
https://doi.org/10.1093/bjsopen/zrab029 DOI: https://doi.org/10.1093/bjsopen/zrab029
Denost Q, Frison E, Salut C, Sitta R, Rullier A, Harji D, et al. A phase III randomized trial evaluating chemotherapy followed by pelvic reirradiation versus chemotherapy alone as preoperative treatment for locally recurrent rectal cancer – GRECCAR 15 trial protocol. Colorect Dis. 2021;23:1909–18.
https://doi.org/10.1111/codi.15670 DOI: https://doi.org/10.1111/codi.15670
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Ghazwan Al Haidari, Arne M. Solbakken, Linn Merete Åsli, Eva Skovlund, Christine Undseth, Marianne Grønlie Guren
This work is licensed under a Creative Commons Attribution 4.0 International License.
